imatinib mesylate has been researched along with Bilateral Headache in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agrawal, S; Baruchel, A; Beverloo, BB; den Boer, ML; Dworzak, M; Kearns, PR; Lancaster, DL; Lehrnbecher, T; Manos, G; Mechinaud, F; Pieters, R; Reinhardt, D; Rizzari, C; Rosenberg, J; Strauss, L; van der Velden, VH; Zwaan, CM | 1 |
| Abdulkadyrov, K; Ayala, M; Babu, KG; Bendit, I; Bullorsky, E; Cortes, JE; de Oliveira, JSR; De Souza, CA; Fellague-Chebra, R; Huang, X; Khanna, S; le Coutre, PD; Liang, Z; Lopez, JL; Owugah, T; Sacha, T; Shah, S; Shen, ZX; Szczudlo, T | 1 |
| Choi, CU; Kim, EJ; Lee, S; Na, JO | 1 |
| Antin, JH | 1 |
| Bauer, H; Frickhofen, N; Hochhaus, A; Jung, B; Märker-Hermann, E; Reiter, A; Walz, C | 1 |
| Benson, K; Chen, G; Cohen, MH; Duan, J; Gobburu, J; Johnson, JR; Kim, SK; Leighton, J; Pazdur, R; Rahman, A; Rothmann, M; Staten, AM; U, KM; Williams, G; Wood, R | 1 |
2 trial(s) available for imatinib mesylate and Bilateral Headache
| Article | Year |
|---|---|
Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Dasatinib; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Headache; Humans; Imatinib Mesylate; Infant; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Nausea; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sample Size; Therapies, Investigational; Thiazoles; Treatment Outcome; Vomiting; Young Adult | 2013 |
Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Protocols; Asia; Biomarkers, Pharmacological; Bone Marrow; Comparative Effectiveness Research; Cytogenetic Analysis; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Europe; Exanthema; Female; Fever; Follow-Up Studies; Headache; Hematologic Diseases; Humans; Imatinib Mesylate; Latin America; Leukemia, Myeloid, Chronic-Phase; Male; Metabolic Diseases; Middle Aged; Philadelphia Chromosome; Pyrimidines; Random Allocation; Treatment Failure | 2016 |
4 other study(ies) available for imatinib mesylate and Bilateral Headache
| Article | Year |
|---|---|
Regression of biventricular Loeffler's endocarditis after early treatment.
Topics: Adult; Aphasia; Cerebral Infarction; Early Diagnosis; Echocardiography; Follow-Up Studies; Headache; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Risk Assessment; Secondary Prevention; Treatment Outcome; Warfarin | 2017 |
A 41-year-old woman with chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Decision Making; Fatigue; Female; Headache; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Stem Cell Transplantation | 2003 |
Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib.
Topics: Adult; Antineoplastic Agents; Arm; Azathioprine; Benzamides; Brain; Cerebellar Ataxia; Cerebellar Cortex; Enzyme Inhibitors; Headache; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunosuppressive Agents; Leukemic Infiltration; Magnetic Resonance Imaging; Male; Memory Disorders; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Paresis; Parietal Lobe; Piperazines; Polyarteritis Nodosa; Prednisone; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Vertigo | 2004 |
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Capsules; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Drug Approval; Exanthema; Headache; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nausea; Piperazines; Pyrimidines; Treatment Outcome; United States; United States Food and Drug Administration; Vomiting | 2002 |